Another limitation in using the combinatory treatment (CDK4/6 inhibitors and DNA damaging agents) is the deficiency of RB1 in some primary cancer cells, which has been linked to poor prognosis and altered response to anticancer treatment [28], [29], [30]. The gene discussed is RB1; the disease is cancer.